Testicular seminoma. A study of 103 cases treated at UCLA.
The records of all patients treated at UCLA with stage I through stage III testicular seminoma, diagnosed in 1956-1983, were reviewed. Histologic subtype, therapeutic protocol, survival, and the incidence of subsequent primary malignancies are examined in this presentation. The 10 year cause-specific survival is 93% for stage I and 70% for stage II patients. Of the four patients initially seen with stage III disease, three have achieved long-term disease-free survival after combined irradiation and chemotherapy. Irradiation of the whole pelvis was not associated with improved control for those patients with previous pelvic surgery. Four patients complained of gynecomastia after therapy, and since none of these patients had elevated human chorionic gonadotropin levels, the gynecomastia was attributed to gonadal failure.
Ellerbroek
N A
NA
Department of Radiation Oncology, UCLA Center for the Health Sciences.
Tran
L M
LM
Selch
M T
MT
Taylor
J M
JM
Parker
R G
RG
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D006063:Chorionic Gonadotropin / Q000097:blood; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004407:Dysgerminoma / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D006801:Humans; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009919:Orchiectomy; D011379:Prognosis; D012042:Registries; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
D006063:Chorionic Gonadotropin; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide